$NOVO B (-3,08%) has submitted a new, higher dose (7.2 mg) of its weight loss drug Wegovy® to the EMA.
In studies: 21 % average weight loss - a third of participants even lost 25 % or more. 🤯
And that with continued good tolerability. For me: a strong signal!
Why is this exciting?
✅ The GLP-1 market is booming, but Novo is showing that they are not only delivering, but also developing.
✅ New dose = new target group: people who couldn't lose enough weight with the 2.4 mg version.
✅ In the long term, it's not just about weight, but also about diabetes, heart, liver and co.
✅ And yes: Europe is a big market - with growing political pressure to finally take obesity seriously.
📈 Will the course take off immediately? Perhaps not spectacularly - but the path is right. I'm staying invested (for the long term). ✌🏻
